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Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease charac-
terized by progressive and only partially reversible symptoms and by considerable negative
consequences such as reductions in functional status and quality of life. Comorbid depression
is highly prevalent in patients with COPD and related to a worse course of the disease. Despite
its negative impact, depression often remains unrecognized and untreated in COPD patients.
This review summarizes the current state of findings from studies examining the effects of
antidepressant treatments in patients with COPD. Reviewed treatment options are antidepres-
sant medical therapy and cognitive-behavioral therapy (CBT). Antidepressant medical trials
include treatments with selective serotonin reuptake inhibitors (SSRI) or tricyclic antidepres-
sants (TCA); CBT was applied using various components. Across both treatment types, the
majority of studies included patients with a wide range of psychiatric conditions and especially
comorbid symptoms of anxiety were often not controlled. Furthermore, greatly varying instru-
ments and methods for assessing depressive symptoms, small sample sizes and rather hetero-
geneous results were observed. This makes the comparison of treatment options rather
difficult and prevents definite conclusions. However, some important implications valuable
for further research were obtained. Some limited data suggested that SSRI might show fewer
side effects than TCA. A few antidepressants as well as beneficial effects in other outcomes
were observed after antidepressant medical treatment. More clearly, CBT showed some poten-
tial in terms of improvements in depressive symptoms, and also in other outcome measures.
Patient compliance seems more promising for CBT than for antidepressant medical treatment.
Overall, the reviewed studies suggest some promising effects for both treatment types andest distance; CBT, cognitive-behavioral therapy; COPD, chronic obstructive pulmonary disease; FEV1,
second; TCA, tricyclic antidepressant; SSRI, selective serotonin reuptake inhibitors; QoL, quality of
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Treatment of depression in COPD 1423effect sizes in studies with significant antidepressant effects were reasonable. However,
future randomized controlled trials comparing antidepressant medical and cognitive-
behavioral therapy will be essential to assess distinct and most favorable treatment effects.
Because recent data is often limited, sound diagnostic criteria of depression and adequate
sample sizes are necessary to draw firm conclusions on the effects of these antidepressant
treatment options in patients with COPD and comorbid depression.
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Chronic Obstructive Pulmonary Disease (COPD) is a chronic
inflammatory lung disease with several systemic manifesta-
tions and includes the subtypes of chronic bronchitis and/or
lung emphysema. It is characterized by progressive and only
partially reversible obstruction of the airways, airflow limi-
tation, chronic cough, increased sputum production and
dyspnea. COPD is associated with severe disability and
dysfunction in everyday life, reduced quality of life and high
socio-economic costs.1e3 About 210million people worldwide
are estimated to suffer fromCOPD. COPD is the fourth leading
cause of death worldwide which accounts for 5% of all human
deaths4 and is projected to rank third by the year 2020.5
Comorbid depressive symptoms and depressive disorders
are highly prevalent in COPDpatients.6 evenwhen exclusively
focusing on the risk of a first episode of depression after COPD
diagnosis.7,8 Recent reviews reported prevalence rates
between 8% and 80%.9e11 A pooled metaanalysis of 13 studies
(NZ 900) demonstrated a prevalence rateof 40%.12 Comorbid
depression in COPD is associated with negative course of
disease including increases inmortality, symptom burden and
hospitalizations as well as decreases in functional status,
quality of life (QoL) and activities.13e19 Accordingly, recent
consensus statementsandguidelines onoptimal care forCOPD
patients emphasized the need of depression assessment and
adequate treatment of persisting depressive symptoms in
COPD patients.10,11,20,21
Despite the high prevalence and considerable negative
impact of depression in COPD, there is a paucity of evidence
regarding its effective management. This fact is already
reflected in the poor detection rates of depression in COPD
patients, but specifically underlined by the inadequate
management thatmany patients receive.11,22,23 For example,a previous study demonstrated that in less than 44% of COPD
patients clinically relevant depression was correctly diag-
nosed and that only 31% of these patients received any
treatment for these psychological comorbidities.24
The present review provides an overview on studies
examining the effects of two commonly used treatment
options in patients with COPD: antidepressant medical treat-
ment and cognitive-behavioral therapy (CBT). Respective
studies were evaluated primarily with respect to effects on
depression, and also on other outcome measures important
for the course of disease.
Antidepressant medication aims at regulation of neuro-
transmitter systems in the brain that have been associated
with depression. In studies with COPD patients, older tricyclic
antidepressants (TCA)andnewer selective serotonin reuptake
inhibitors (SSRI) havebeen tested. TCAhave successfully been
applied for decades and their antidepressant effect is caused
by inhibiting the reuptakeof the neurotransmitters serotonin,
noradrenalin and dopamine from the synaptic cleft. This
increase in available neurotransmitters enhances synaptic
signal transmission and is supposed to adjust the deficiency of
second messengers that underlie depression mechanisms.
Today, SSRI are themost commonly prescribed antidepressant
drugs.25,26 Theyacton serotonin transporters andenhance the
concentration of serotonin in the synaptic cleft by inhibiting
the reuptake into the presynapse. In contrast to TCA, they are
more selective because they do not impact on other mono-
amine transporters. Furthermore, when compared to TCA,
SSRI are associated with less unwanted side effects such as
sedation, dizziness and anticholinergic symptoms, which
leads to enhanced patient compliance.27,28
CBT is an evidence-based psychological intervention and
includes a wide range of established behavioral and cognitive
techniques for different mental disorders.29 Recommended
1424 A. Fritzsche et al.elements of CBT for depression include behavioral activation,
enhancing competency through skill-building exercises and
establishing a more adaptive cognitive style.30 Cognitive
components target automatic thoughts and their influence on
feelings,31 awareness of cognitive biases associated with
physical limitations,32 problem-solving techniques, sleep-
management skills33 and techniques such as thought stop-
ping and self-instructional training to reduce maladaptive
thoughts.34 Behavioral components can involve enhancement
of activities, but also non-specific relaxation or stress
management techniques. CBT has been demonstrated to be
effective in reducing depressive symptoms in all age groups
and is therefore recommended as antidepressant therapy for
all age groups including elderly patients,35 which form the
majority of COPD patients. The general elements of CBT
(behavioral activation, enhancing competency through skill-
building exercises and establishing cognitive changes) are
similar when treating patients with vs. without COPD.
However, because some symptoms of COPD and depression
overlap (e.g., fatigue, sleep problems, reduced activity
levels), it is necessary to carefully differentiate between
psychological and physiological origin of these symptoms in
COPD patients and to select appropriate interventions
accordingly. Moreover, CBT in COPD patients should include
specific educational elements about COPD, for example tar-
geting the vicious circle of dyspnea or depression-related
activity avoidance-deconditioning-more dyspnea and more
depressive symptomsand respective interventions to increase
the physical activity level. In addition, specific goals for the
symptom management of the chronic lung disease31 and
respective specific coping skills (e.g., breathing trainings,
symptommanagement in thepublic, cognitive interpretations
of physical symptoms) should be considered in antidepressant
CBT treatments in COPD.34
Method
A literature search was conducted for studies examining the
impact of antidepressant medical treatment and cognitive-
behavioral therapy on depressive symptoms using the OVID
(PsycINFO, PSYNDEX, PsycCRITIQUES, MEDLINE and EMBASE)
and PubMed databases. Essential keywords were COPD,
cognitive-behavioral therapy, CBT, depression, psycho-
therapy, and antidepressant. Furthermore, additional litera-
turewas selected fromarticles’ reference lists. For significant
antidepressant treatment effects in single studies, Cohen’s
d was calculated as a measure of effect size with d Z 0.2
denotinga small effect,dZ0.5denotingamediumeffect and
dZ 0.8 denoting a large effect.36
Results
Antidepressant medical treatment
Effects of tricyclic antidepressant treatment (TCA)
An overview of studies examining the effects of TCA is
provided in Table 1. From the identified five studies, only one
randomized,double-blindplacebo-controlled trialwasable to
show improvements over placebo after 12 weeks of nortrip-
tyline regarding depressive symptoms, anxiety, respiratorysymptoms, physical comfort and functioning.37 This was also
the only study with depression being diagnosed according to
DSM-III criteria and with an acceptable sample size and drop-
out rate. The effect size for the difference in reduction of
depressive symptoms between placebo and nortriptyline was
dZ 1.07. A second study suggested at least some improve-
ments in depressive symptoms after eight weeks of desipra-
mine, but similar effects were found after eight weeks of
placebo treatment.38 In a double-blind crossover trial
regarding hospitalized veterans, doxepin hydrochloride did
not lead to significant improvements in exercise capacity or
depression scores.39 A small uncontrolled study reported
faster recovery in 10 patients of all COPD stages after an
imipramineediazepam combinationwithout providing details
on measurement instruments.40 Overall, the majority of
studieswere of considerably small sample sizewith half of the
studies including less than 14 patients. All these studies
demonstrated high drop-out rates. For example, only 5 out of
26 patients completed the trial in one of these studies.41
Reasons for the high number of drop-outs were mostly strong
side effects. In addition, only two studies used DSM criteria to
diagnose depression and a great variety of measurement
instruments for depression was employed across studies.
Moreover, comorbid symptoms of anxiety were reported in at
least two studies and were not controlled for in other studies,
which might have interacted with antidepressant treatment.
Effects of selective serotonin reuptake inhibitor
treatment (SSRI)
An overview of the studies is shown in Table 2. From the
identified six studies, three used a randomized double-blind
placebo-controlled design, but these studies reported con-
flicting results. First, an increased response ratewas found for
well-tolerated fluoxetine over the placebo after five or more
weeks of treatment.42 Second, paroxetine treatment led to
large and significant differences in emotion and mastery
domains of disease-specificQoL scores and to nonsignificante
but clinically important e differences in dyspnea and fatigue
scales that were nonsignificant due to a lack of power in the
small sample.43 Third, after six weeks of blinded paroxetine
vs. placebo treatment, no differences between groups could
be found.44 Improvements in depression were correlatedwith
increases in walking distance. However, three months of
unblinded treatment revealed significant improvements in
depression scores,walking distanceandQoL.44 Effect sizes for
depression reduction varied between dZ 1.27 and dZ 1.98,
depending on the applied instruments.
Three other studies exclusively reported descriptive
results. It could be demonstrated that five of six patients who
were treated with sertraline for six weeks showed improve-
ments in daily living activities.45 Participantswith psychiatric
conditions felt subjective improvements, but no significant
changes in physiological measures were observed. A further
study described seven patients with obstructive airways
disease (including asthma) that received sertraline in addi-
tion to their regularmedications.46 Improvements in dyspnea
and some subjective improvements in exercise tolerance
were observed, but not in FEV1. All participants tolerated
sertraline well. In another study, the acceptability of fluox-
etine, however, was found to be very poor in depressed
elderly patients with COPD and only four of seven patients
responded to it.47
Table 1 Antidepressant medical treatment drug therapy in COPD patients; TCA treatment trials.
TCA study Study design Intervention Participants Instruments Outcome ESa for depression
Gordon et al.
(1985)
Randomized
double-blind
crossover trial
Desipramine for 8 wks and
placebo for 8 wks, order
was blinded. Initial
dose 25 mg/d, increased
weekly to maximum
tolerated (not
exceeding 100 mg).
N Z 13, stable COPD
outpatients stage III. None
met DSM-III criteria of
depression. N Z 6
completed trial. Anxiety
not assessed.
BDI and Zung
self-rating
depression scale
Depression scores improved
significantly after treatment
with placebo and with
desipramine. No effect on
physiological measures.
d Z 0.85 for
desipramine
group, d Z 0.99
for placebo group
Light et al.
(1986)
Randomized
double-blind
crossover trial
Doxepin hydrochloride for 6
wks and placebo 6 wks,
order was blinded. Doses
received as tolerated.
Maximum dose 105 mg/d.
N Z 12 outpatients with
COPD stage III and high
levels of depression. N Z 9
completed trial. Anxiety
scores higher than average
for hospitalized veterans.
BDI; 12MWD;
Spielberger’s
state-trait
anxiety
inventory
No significant improvements
in exercise capacity or
depression and anxiety
scores. Increase in 12MWD
correlated with improvements
in depression or anxiety.
d Z 0.46 for
placebo, d Z 0.37
for doxepin
hydrochloride group
Sharma et al.
(1988)
Double-blind
method
Imipramineediazepam
combination
N Z 10 consecutive COPD
patients (all stages)
evaluated for depressive
disorders
N.A. Helped depressed patients
recover faster, but diazepam
may trigger respiratory failure.
e
Borson et al.
(1992)
Randomized
double-blind
placebo-
controlled trial
Nortriptyline vs. placebo
for 12 wks ¼ of 1 mg/kg
of body weight increased
weekly until 1 mg/kg
of body weight.
N Z 36 in patients with COPD
stage IIeIII and comorbid
depressive disorder (DSM-III
criteria). N Z 30 (n Z 17
placebo) completed trial. 83%
with significant anxiety
symptoms
CGI, Hamilton
depression
rating scale;
PRAS; 12MWD;
PFSI; SIP;
Dyspnea
questionnaire
Superior improvements for
nortriptyline group in depression.
Further improvements in anxiety,
respiratory symptoms, physical
comfort and day-to-day
functioning. No change in
physiological measures
dkorr Z 1.07
Stro¨m et al.
(1995)
Randomized
double-blind
placebo-
controlled trial
Protriptyline vs. placebo
for 12 wks, 10 mg/d.
N Z 26 (n Z 12 placebo)
stable COPD patients, at
least stage II, with mild to
moderate hypoxaemia. N Z 5
completed trial
HADS, MACL; SIP;
Dyspnea
(self-developed
scale)
No improvement in depression
or anxiety scores, arterial
blood gas tension, spirometry
values, dyspnea or QoL scores.
High rates of anticholinergic side
effects
dkorr Z 0.33
/dZ a day; 12MWDZ 12 min walking distance; BDIZ Beck Depression Inventory; CGIZ Clinical Global Improvement Scale; COPDZ chronic obstructive pulmonary disease; ESZ effect
size; HADS Z Hospital Anxiety and Depression Scale; MACL Z Mood Adjective Checklist; n.a. Z not available; PFSI Z Pulmonary Functional Status Instrument; PRAS Z Patient-Rated
Anxiety Scale; QoL Z Quality of life; SIP Z Sickness Impact Profile (generic health status); Stage IeIV Z Global Initiative for Obstructive Lung Disease (GOLD) standard for severity of
COPD; TCA Z tricyclic Antidepressant; wks Z weeks.
a Effect sizes are reported when available or calculation possible.
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Table 2 Antidepressant medical treatment in COPD patients; SSRI treatment trials.
SSRI study Study design Intervention Participants Instruments Outcome ESa for depression
Papp et al.
(1995)
Pilot study;
descriptive
Sertraline for 6 wks,
12.5 mg/d. Increased
to 100 mg during first
2 wks.
N Z 6 consecutive COPD (severity
not reported) outpatients, 3 with
comorbid anxiety or depression.
n.a. Well tolerated, all reported general
sense of well being. 5 showed
improvements on daily living
activity scale. No improvements
in physiological parameters,
subjective improvement in
psychiatric conditions.
e
Smoller et al.
(1998)
Case reports
(6 retro-1
prospectively)
Sertraline (25e
100 mg/d) added to
regular medication.
Varying durations.
N Z 7 patients with obstructive
airways disease (incl. asthma).
Psychiatric conditions varied.
Varied across
patients
Improvements in dyspnea,
regardless of comorbidities,
but not in FEV1. Some reported
improvements in exercise tolerance,
mood, and anxiety.
e
Evans et al.
(1997)
Randomized
double-blind
placebo-
controlled trial
Fluoxetine vs. placebo
for 8 wks, 20 mg/d.
N Z 82 acute geriatric medical
inpatients with depression (ELDRS,
GMS). N Z 42 (n Z 21 placebo)
completed trial. N Z 38 with
respiratory diseases.
HAMD, ELDRS,
GMS
No significant difference between
groups in response rate. Trend for
fluoxetine group to respond better
than controls after 8 wks (subjective
report). Significantly more recovery
from depression after 5 wks fluoxetine.
e
Yohannes et al.
(2001)
Single-blinded,
open study
Fluoxetine for 6 mths,
20 mg/d.
N Z 57 COPD patients stage IIeIII
and depression (GMS). N Z 14
agreed to fluoxetine, N Z 7
completed. Anxiety not assessed.
GMS and
MADRS;
MRADL, BPQ
72% refusal rate. Of the 7 who
completed trial, 4 responded to
fluoxetine (criteria for major
depression). 5 withdrew because of
adverse side effects.
e
Lacasse et al.
(2004)
Randomized
double-blind
placebo-
controlled trial
Paroxetine vs. placebo
for 12 wks, 2 patients
10 mg/d, other
tolerated 20 mg/d.
N Z 23 outpatients with COPD
(average stage III) and significant
depressive symptoms (GDS).
N Z 15 (n Z 7 placebo) completed
trial. Anxiety not assessed.
GDS; SF-36,
CRQ
GDS improved significantly after paroxetine
but not after placebo. Adjusted between-
group mean difference ns. Significant
improvements in emotion and mastery
domains and clinically important
improvement (ns.) in dyspnea and fatigue
scale after paroxetine. Respiratory stable.
e
Eiser et al.
(2005)
Randomized
double-blind
placebo-
controlled trial
Paroxetine vs. placebo
for 6 wks, unblinded
paroxetine for 3 mths.
20 mg/d.
N Z 28 stable outpatients with
COPD stage IIeIII and depression
(ICD-10 criteria)
HADS, BDI and
MADRS. SGRQ;
6MWD
6 wks of blinded treatment led to ns.
between-group differences. After
unblinded 3 mths of treatment, depression
scores, walking distances and QoL had
significantly improved.
HADS-D:
d Z 1.33
BDI: d Z 1.27
MADRS:
d Z 1.98
/d Z a day; 6MWD Z Six-min walking distance; BDI Z Beck Depression Inventory; BPQ Z Breathing Problems Questionnaire; COPD Z chronic obstructive pulmonary disease;
CRQ Z Chronic Respiratory Questionnaire (COPD disease-specific QoL inventory); ELDRS Z Evans Liverpool Depression Rating Scale; FEV1 Z Forced expiratory volume in 1 s;
GDS Z Geriatric Depression Scale; HADS Z Hospital Anxiety and Depression Scale; GMS Z Geriatric Mental State; HAMD Z Hamilton Depression Rating Scale; MADRS Z Montgomery-
Asberg Depression Rating Scale; mthsZ months; MRADLZ Manchester Respiratory Activities of Daily Living Questionnaire; n.a.Z not available; ns.Z not significant; SF-36Z Medical
Outcome Survey e Short Form 36 (general health related QoL); SGRQ Z St. George’s Respiratory Questionnaire (perceived health status); SSRIZ selective serotonin reuptake inhibitor;
Stage IeIV Z Global Initiative for Obstructive Lung Disease (GOLD) standard for severity of COPD; QoL Z Quality of life; wks Z weeks.
a Effect sizes are reported when available or calculation possible.
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Table 3 Treatment trials using CBT components in COPD patients.
CBT study Study design Intervention Participants (controls) Instruments ESa for depression
Adams et al.
(2006)
Pilot study,
randomized
controlled trial
6 weekly group sessions
(90 min) of CBT vs.
general health education.
N Z 22 (11Zgeneral health
education) patients with
COPD stage IIIeIV and
moderate levels of anxiety.
BDI; BAI,
SGRQ
No between-group
differences in BAI or
BDI scores. CBT group
improved in SGRQ
more than education
group.
e
Cully et al.
(2009)
Case reports ACCESS intervention;
6 individual active
treatment sessions
(45min), telephone
possibility.
N Z 3 male veterans with
cardiopulmonary diagnoses.
N Z 2 COPD patients; stage
I and III; not meeting
diagnostic criteria of
depression or anxiety
(MINI); BDI>13.
BDI-II; STAI,
CRQ, SF-36,
CSQ
Improvements in
anxiety and
depression as well
as functional status
were observed and
lasted to 3-months
follow-up.
e
de Godoy &
de Godoy
(2003)
Randomized
controlled trial
12-week treatment.
G1 with physical exercise
(24 sessions), education
(3 sessions), physiotherapy
(24 sessions) plus
psychotherapy (12 sessions)
vs. G2, same treatment
without psychotherapy.
N Z 30 (16ZG2) COPD
outpatients; more than
two thirds at least stage III.
Half the patients (53.3% of
G1,
46,6% of G2) with at least
low
levels of anxiety or
depression
(BDI>11, BAI>9).
BDI; BAI,
6MWD
Both groups increased
walking performance,
G1 almost twice as
much (group
differences ns.). G1
improved in
depression and
anxiety levels,
G2 did not.
dkorr Z 0.68
de Godoy et al.
(2005)
Randomized
controlled trial
12-week treatment. G1: PRP
(physical exercise, individual
psychotherapy sessions,
group educational sessions,
physical therapy); vs. G2:
PRP without physical exercise;
vs. G3: PRP without
psychotherapy.
N Z 49 (G1 Z 19; G2 Z 16,
G3Z14) consecutive
patients
with COPD stage IIeIII. Mild
to
moderate levels of anxiety
and
depression (BDI).
BDI; BAI,
SGRQ,
distance
walked-
weight
product
G1 and G2 patients
improved in anxiety
and depression as well
as SGRQ and exercise
tolerance. G3 improved
in anxiety.
G1: d Z 1.58 G2:
d Z 1.11
de Godoy et al.
(2009)
Long-term
evaluation of
pulmonary
rehabilitation
program (PRP)
12 weeks PRP (24physical
exercise, 24respiratory
rehabilitation, 12group
psychotherapy, 3education).
Pre-, post-PRP and two years
later (current).
N Z 30 outpatients with
COPD
stage III - IV. 50% with
clinically
significant depression (BDI);
46,6%
with clinically significant
anxiety.
BDI; BAI,
SGRQ,
6MWD
Post-PRP evaluation
revealed improvements
in BDI, BAI and SGRQ
Activity, Impact and
Total scores as well as
in 6MWD. After two years
no significant changes
since post-treatment
except for SGRQ Impact
score (borderline).
pre to post evaluation:
d Z 0.90. Post to
current
evaluation: d Z 0
(continued on next page)
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Table 3 (continued)
CBT study Study design Intervention Participants (controls) Instruments ESa for depression
Emery et al.
(1998)
Randomized
controlled trial
EXESM vs. ESM and WL for
10-week period. Small groups.
N Z 79 (EXESM Z 29;
ESM Z 25;
WLZ25) COPD outpatients
stage III.
Subclinical depression
(CES-D).
CES-D;
Bradburn
Affect
eBalance
Scale; STAI,
SCL-90-R,
MHLC, SIP,
cognitive
assessments
EXESM and WL groups
showed reductions in
depressive symptoms
and SIP scores. EXESM
showed improvements
in anxiety and
organized verbal
processing. All groups
increased mental
efficiency performance.
EXESM: d Z 0.80
WL: d Z 0.42
Heslop et al.
(2009)
Non-randomized
study
Nurse-led individualized CBT
program with average of 4
sessions (range 2e13).
N Z 10 COPD outpatients,
80%
stage III. Doctors evaluated
depression and/or anxiety
being
significant.
HADS-D;
HADS-A,
FEV1
Improvements in anxiety
and depression scores
and less hospital
admissions during the 6
months after CBT
compared to 6 months
before.
d Z 1.53
Hynninen et al.
(2010)
Randomized
controlled trial
Group CBT (7 weekly 2h
sessions) vs. standard care
plus telephone contact every
2 weeks. Masters-level
psychology
student in charge.
N Z 51 (26Zstandard care)
COPD
outpatients, stage II.
Prescreened
for depression and anxiety
(BAI>15
and/or BDI>13). 33% met
DSM-IV
criteria for mood-disorder,
25.5%
for an anxiety disorder;
45.1% for
either.
BDI-II; BAI,
SGRQ, PSQI,
actigraphy,
CSQ
CBT group improved in
anxious and depressive
symptoms, control group
did not. Sleep efficiency
improved from post-
treatment to follow-up,
but no subjective
improvement reported.
Post-treatment: dZ0.7
Follow-up: d Z 1.0
Kunik et al.
(2001)
Randomized
controlled trial
One 2h session of group CBT vs.
one 2h session of COPD
education.
Both groups received 6
additional
weekly calls.
N Z 48 (29ZCOPD
education) COPD
in- and outpatients.
Recruited
regardless of depressive or
anxious
symptoms. Mild levels of
anxiety and
depression (GDS).
GDS; BAI,
SF-36,
6MWD,
CSQ
CBT group was superior
to education in reduction
of depressive and anxious
symptoms. No change in
COPD severity or physical
functioning.
dkorr Z 0.52
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Kunik et al.
(2008)
Randomized
controlled trial
8 sessions of CBT group
treatment
(1h) vs. COPD education
(45min þ
discussion).
N Z 108 (56ZCOPD
education) COPD
patients stage III. BDI>14
and/or
BAI>15. 53.2% with DSM-IV
diagnosis
of depression, 38.1% of
anxiety and
62.2% either.
BDI-II; CRQ,
SF-36, BAI,
6MWD,
service
use
Improvements in BDI-II, BAI,
CRQ, SF-36 mental health
score and emotional composite
score and 6MWD. Differences
between groups ns., most
improvements larger for CBT
group. Improvement up to 44
weeks.
COPD education:
d Z 1.05, CBT:
d Z 1.45
Lisansky &
Clough (1996)
Pilot study; one
group pre- and
post
8 weekly sessions (90min) of
cognitive-behavioral self-help
educational program, led by
nurses.
N Z 8 participants with
stage II - III COPD.
Symptom Questionnaire;
SIP, General-
Cognitive Error
Questionnaire,
COPD-Cognitive-
Error
Questionnaire
No significant change in
depressive symptoms.
Decreases
in Psychosocial and Total
SIP
Scores, General-
Cognitive Error
Questionnaire
personalization
subscale and COPD-
Cognitive
Error Questionnaire
selective
abstraction subscale.
d Z 0.41
Stanley et al.
(2005)
Case reports 8 weekly 1h sessions of group
CBT
(cognitive approach for
anxiety,
behavioral activation for
depression).
N Z 5 male veterans with
COPD
stage II e III and BDI >13
and/or
BAI >15. N Z 3 with Major
Depression (DSM-IV
criteria).
BDI; BAI,
CRQ,
SF-36
N Z 3 improved in BDI scores
evident one year after treatment.
Same patients improved in BAI
scores. Some improvements in
CRQ and SF-36.
e
6MWD Z Six-minute walking distance; ACCESS Z Adjusting to Chronic Conditions using Education, Support, and Skills; actigraphy Z objective sleep efficiency; BAI Z Beck Anxiety
Inventory; BDI Z Beck Depression Inventory; CBT Z cognitive-behavioral therapy; CES-D Z Center for Epidemiological Studies e Depression Inventory; COPD Z chronic obstructive
pulmonary disease; CRQ Z Chronic Respiratory Questionnaire (COPD disease-specific QoL inventory); CSQ Z Client Satisfaction Questionnaire; ES Z effect size; ESM Z Education and
stress management; EXESM Z Exercise, education and stress management; FEV1 Z Forced expiratory volume in 1 s; G1 Z Group 1; G2 Z Group 2; G3 Z Group 3; GDS Z Geriatric
Depression Scale; HADS Z Hospital Anxiety and Depression Scale; HADS-A: anxiety scores; HADS-D: depression scores; MHLC Z Multidimensional Health Locus of Control inventory;
MINI Z Mini international Neuropsychiatric Inventory; ns. Z nonsignificant; PRP Z Pulmonary Rehabilitation Program; PSQI Z Pittsburgh Sleep Quality Index (subjective sleep qual-
ity);SCL-90-RZ Hopkins Symptom Checklist; SF-36Z Medical Outcomes Survey Short Form-36 (general health related QoL); SGRQZ St. George’s Respiratory Questionnaire (perceived
health status); SIPZ Sickness Impact Profile (generic health status); Stage IeIVZ Global Initiative for Obstructive Lung Disease (GOLD) standard for severity of COPD; STAIZ Spielberger
Anxiety Inventory Trait Anxiety; WL Z Waiting List.
a Effect sizes are reported when available or calculation possible.
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1430 A. Fritzsche et al.Overall, most studies were of small sample size and/or
demonstrated high drop-out rates. Similar as in TCA studies,
a great variety of measurement instruments for depression
was used across the studies e none used DSM criteria e and
comorbid symptoms of anxiety were either not controlled for
or not excluded. This might have interacted with antide-
pressant treatment.
Effects of cognitive-behavioral therapy (CBT)
An overview of studies examining the effects of CBT is
provided in Table 3. Overall, no study exclusively tested COPD
patients with comorbid depression only and no trial tested
antidepressant treatment independently from effects on
anxiety. From the 12 studies identified, six were randomized
and controlled trials. One study was a long-term evaluation
and the other studies were non-randomized trials, case
reports and pilot studies.
Four of the randomized controlled trials showed signifi-
cantly improved depression scores for the treatment groups,
but not for the control groups.34,48e50 The remaining two trials
revealed treatment effects for depressive symptoms.32,33
These were not observed for stress management (CBT-
format) without exercise, however, antidepressant effects
were also obtained in the waiting list condition.32 Further-
more, no superiority compared to aneducational intervention
was found.33
One randomized and well controlled trial with adequate
sample size and application of diagnostic DSM criteria
reported significant improvements in depressive symptoms
after CBT, but not after enhanced standard care.48 This
improvement lasted up to the 8-months follow-up. The
objectively measured sleep efficiency had improved at 8-
months follow-up, whereas the subjectively reported
experience of sleep was rated poor at all times. Other
secondary outcomes were not improved through reduction
of mental health symptoms.
Kunik et al.34 have found a single two-hours-session of CBT
to reduce depressive symptoms in mild depressed COPD
patients. No reduction was observed in the control group
receiving COPD education.
In two other randomized controlled trials, only treatments
including psychotherapy led to significantly improved
depression levels.49,50 The group receiving additional
psychotherapy improved almost twice as much in walking
ability as the group without.49 A long-term evaluation of the
same pulmonary rehabilitation program that included
psychotherapy showed improvements in anxiety, depression,
QoL and 6MWD to last up to 24-months of follow-up.51
All remaining studies used small sample sizes. Significant
improvements in depression scores and disease specific and
generic QoLwere observed after CBTwith eight sessions52 and
after a similar intervention.53 In a nurse-led CBT individual-
ized program, depression scores were significantly improved
in patients with COPD after an average of four sessions, which
was paralleled by reductions in mean hospital admissions.54
A cognitive-behavioral self-help educational program
revealed significant decreases in the Psychosocial and Total
Sickness Impact Profile (SIP) scores.55 This indicates improve-
ments in generic health status and improvement in the
disease’s impact on everyday life. A pilot study revealed
superior improvement in perceived health status after six
group sessions of CBT compared to general health education.However, no group differences in depression or anxiety scores
were retrieved.56
Across studies that found significant antidepressant
effects in favor of CBT, the mean effect size was d Z 0.93
(range: 0.52e1.58).Discussion
Although depression is highly prevalent in COPD and associ-
ated with negative course of disease,13,19,57,58 it often
remains undiagnosed and/or untreated in these
patients.18,24,43,59 This review aimed at summarizing the
current stateof findings from trials that examined theeffects
of antidepressant medical treatments and CBT in patients
with COPD.
Overall, antidepressant medical as well as CBT treatment
trials in COPD patients are rare and heterogeneous in their
results. Therefore, firm conclusions on the effectiveness of
these treatment options are difficult to draw. A variety of
reasons for these inconclusive results become obvious in this
review. First, many trials have not used sound diagnostics for
confirming clinical significant depressionbasedonestablished
DSM criteria as an inclusion criterion for their participants.
Rather, questionnaire scores from various instruments were
used to confirm a certain level of depressive symptoms. Other
trials included patients regardless of depressive symptoms or
comorbid other symptoms of psychopathology. Therefore, it
can be assumed that included nondepressed participants
might have benefited less from some of the evaluated inter-
ventions leading tobiasedoutcomes. Second,manytrials have
treated depression not independently from anxiety, which
might have led to confounded results and less optimal treat-
mentofdepression inCOPDpatients,particularly inCBTtrials.
This is due to the fact, that patients with depression and
comorbid anxiety disorder needed more time to recover from
depression than those with depression alone60,61 and have an
higher risk for chronicity in depression and treatment resis-
tance.62,63 Furthermore, CBT treatments of depression and
anxiety differ with respect to included therapeutic
elements.64
Third, COPD education has often been regarded as
a control condition, which led to sub-optimally educated
treatment groups. Evidence suggests that patient education
can be an important base for further treatment in COPD,65,66
which might have reduced potential treatment effects.
Fourth, many trials were considerably limited by their small
sample size, often as a result of high drop-out rates, in
particular during antidepressant medical trials. Therefore,
a lack of significant treatment resultsmight have been caused
by limited statistical power. Finally, instruments measuring
QoL were often not included in trials, thus, limiting conclu-
sions onpossible treatment effects on this important outcome
measure in COPD patients.
Bearing all the aforementioned shortcomings in mind, at
least some conclusions and suggestionsmight be derived from
the reviewedstudies, inparticular fromthe larger randomized
controlled trials.
In antidepressant medical trials, compliance with and
feasibilityofmedical treatments has been reportedas lowand
a preference of patients for psychological treatments has
been assumed.47 The main reasons for limited compliance or
Treatment of depression in COPD 1431refusal of antidepressant medication were fear of side
effects, frustration with taking many medications, and/or
denial of psychological symptoms.24,42 Stage and colleagues67
have hypothesized that doses of antidepressant medications
might have to be lower in elderly populations such as patients
with COPD which could have contributed to the reported side
effects. Diazepam may even trigger respiratory failure.40
However, some promising results have been obtained. For
TCA treatment, Borson et al.37 found nortriptyline to be
superior to placebo with an effect size of d Z 1.07 for the
reduction of depressive symptoms. Interestingly, respiratory
symptoms, physical comfort and day-to-day functioning
improved aswell. For SSRI treatment, Eiser et al.44 have found
paroxetine treatment tobeveryeffective after threemonths.
An important direction for future research could be the
possible triad with smoking cessation. Smoking is not only
a major cause for the development of COPD, but also closely
linked to depression.68 Because smoking cessation, which is
generally regarded to be essential for COPD treatment,20 was
improved in studies using the antidepressants bupropion and
nortriptyline,69 examining the effects of antidepressant
medications regarding the interactions between antidepres-
sant effects and smoking behavior in COPD patients appears
highly important.
When comparing the two medical treatments, the appli-
cability of TCA for patients with COPD seems to be more
difficult due to more side effects, whereas SSRI seem to be
more promising with regard to their effects on symptoms of
depression.70,71 However, future randomized controlled trials
are clearly warranted to proof these observations.
The identified CBT trials have shown some promising
potential in terms of reducing depressive symptoms in
patients with COPD as well as improving subjective and
objective markers of the course of disease. However,
a depression specific CBT approach that either excludes
comorbid anxiety or that specifically targets comorbid symp-
toms of depression and anxiety has yet to be evaluated in
patients with COPD. The observed broadness of inclusion
criteria,employedcomponentsanddurationofCBTmakes the
comparison of the reviewed treatment trials difficult. Some
trials have revealed antidepressant effects of CBT when
compared to control conditions.34,48,50 Others showed
improvements of CBT groups in walking or exercise
ability.33,49,50 Yet other studies have found comparable
effects in CBT treatment groups and control groups32,33 and,
thus, no superiority of CBT in terms of antidepressant effects.
However, compliance and satisfaction with CBT treatments in
patients with COPD seem to be promising34,48e50,52 and the
need for behavioral approaches is emphasized.72 Neverthe-
less, similar to the medical treatment option, future
randomized controlled trials are clearly warranted to draw
definite conclusions on the antidepressant effects of CBT in
patients with COPD.
When comparing the two treatment options e antide-
pressant medical treatment and CBT e some aspects seem to
be important. COPD education could be an effective first step
beforethe specificeffectsofantidepressant treatmentsareto
be tested or compared in patients with COPD.66,67 COPD
education might enhance perceived self-efficacy, thus,
increasing the motivation to engage in any form of treat-
ment.66 For example, patient-perceived mastery over COPD
has been suggested to be negatively related to mental healthengagement.73 Whereas compliance to CBT seems to be good
inelderly patients,35 antidepressantmedical treatmentmight
be less accepted as discussed above.47 Therefore, some
authors conclude CBT to be the treatment of choice,74 but
a direct comparison of CBT and antidepressant medical
treatment in COPD patients is currently lacking.
Moreover, further research is needed to test the effects of
both treatment options with regard to the severity of
depression. For example, Mikkelsen et al.16 state that mild
depressionmight be treated with CBTwhereas cases of major
depression shouldbe treatedpharmacologically. Additionally,
most of the reviewed studies did not examine physical and
psychological outcome measures together. Because some
studies demonstrated improvements in both outcome
domains,44,75 future studies should include both, physical and
psychological outcome measures.
Conclusion
The high prevalence of depression in patients with COPD and
its negative impact on the course of disease make the treat-
ment of comorbid depression an important issue for the
diseasemanagement.Antidepressantmedical treatmentsand
CBTare two treatmentoptionswith somepromising potential.
However, the current data base for these treatments is
considerably limited, both by the small number of studies and
several methodological shortcomings, leading to heteroge-
neous results. Further studies with larger sample sizes and
improved diagnostics are clearly needed for firm conclusions
about the effects of these treatments on psychological and
physical well being in patients with COPD.Author contributions
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